

IN THE CLAIMS

Claims 1-26 (Canceled)

27. (Previously Presented) A method of treatment, comprising:

separately delivering a treatment agent and a barrier having a binding member to a tissue, the binding member having a property adapted to couple to a surface of the tissue, wherein the barrier is present in an amount sufficient to permit transport of the treatment agent from the tissue at a lower rate than transport in the absence of the barrier component, wherein the barrier is biodegradable and hinders transport of the treatment agent away from the tissue but allows the treatment agent to migrate toward the tissue.

28. (Previously Presented) A method comprising:

delivering a treatment agent to a tissue, the treatment agent within a barrier having a binding member and a delivery carrier,

the binding member having a property adapted to couple to a surface of the tissue, wherein the barrier is present in an amount sufficient to permit transport of the treatment agent from the tissue at a lower rate than transport in the absence of the barrier component,

wherein the barrier is biodegradable and hinders transport of the treatment agent away from the tissue but allows the treatment agent to migrate toward the tissue,

wherein the binding member is a counter ion of an ionic member on the surface of the tissue for attachment of the binding member.

29. (Original) The method of claim 28, wherein the binding member is a cationic member and the member on the surface of the tissue is an anionic member.

30. (Original) The method of claim 28, wherein the binding member is an anionic member and the member on the surface of the tissue is a cationic member.

31. (Original) The method of claim 27, wherein the barrier component includes an amino acid.

32. (Original) The method of claim 31, wherein the amino acid is poly-L-lysine.

Claims 33-47 (Canceled)

48. (Previously Presented) The method of claim 27, wherein the tissue is myocardial tissue.

49. (Previously Presented) The method of claim 27, wherein the binding member is ionic and has a pKa value between 6 and 10.

50. (Previously Presented) The method of claim 27, wherein the binding member is capable of sharing electrons with a member of the surface of the tissue.

51. (Previously Presented) The method of claim 27, wherein delivering comprises delivering the treatment agent before the barrier.

52. (Previously Presented) The method of claim 27, wherein delivering comprises delivering the treatment agent after the barrier.

53. (Previously Presented) The method of claim 27, wherein prior to delivering the barrier, the method comprises delivering a charged molecule to the tissue.